Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study
Serum C-reactive protein (CRP) is a marker of acute inflammatory response and has been associated with health outcomes in some studies. Inflammation and immune response may have potential prognostic implications for breast cancer survivors. The Women's Healthy Eating and Living Study includes 2...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2014-01, Vol.23 (1), p.189-199 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 199 |
|---|---|
| container_issue | 1 |
| container_start_page | 189 |
| container_title | Cancer epidemiology, biomarkers & prevention |
| container_volume | 23 |
| creator | VILLASENOR, Adriana FLATT, Shirley W MARINAC, Catherine NATARAJAN, Loki PIERCE, John P PATTERSON, Ruth E |
| description | Serum C-reactive protein (CRP) is a marker of acute inflammatory response and has been associated with health outcomes in some studies. Inflammation and immune response may have potential prognostic implications for breast cancer survivors.
The Women's Healthy Eating and Living Study includes 2,919 early-stage breast cancer survivors with serum collected 2 years postdiagnosis and follow-up for clinical outcomes over approximately 7 years. CRP concentrations were measured using high-sensitivity electrochemiluminescence assay. Outcomes, including all-cause mortality, breast cancer-specific mortality, and additional breast cancer events were oncologist verified from medical records and death certificates. Cox proportional hazards models were conducted with adjustment for potential confounding factors to generate HRs and 95% confidence intervals (CI).
CRP concentrations in women diagnosed with breast cancer were associated with death due to any cause, death due to breast cancer, and additional breast cancer events, after adjustment for sociodemographic and cancer characteristics (lnCRP: P < 0.05 for all three outcomes). The HR for women with (vs. without) acute inflammation suggests a threshold effect on overall survival, rather than a dose-response relationship (≥ 10.0 mg/L vs. |
| doi_str_mv | 10.1158/1055-9965.EPI-13-0852 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3911892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490699209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-9a0dfd5207272848360262feb3b6180337a86008dd84c1ddd822f875ea45fc823</originalsourceid><addsrcrecordid>eNpVkVtrGzEQhUVoyf0ntOilkJdNdN2V-lBojXMBQ02TkKcgZElrq6wlR9Ia8u-zS5ykfZqB-ebMcA4AXzA6x5iLC4w4r6Ss-fl0flNhWiHByR44xJyKqmk4_zT0b8wBOMr5L0KokZzvgwPCCEES00PwOI-5WK-XIWaf4aT647QpfuvgPMXifIA6WPgrOZ0LnOhgXIK3fdr6bUx55Tff4aUP1odlhm2Ka1hWDj5cT2fwtvT2-QR8bnWX3emuHoP7y-nd5Lqa_b66mfycVYYxXCqpkW0tJ6ghDRFM0BqRmrRuQRc1FojSRosaIWGtYAbboRDSioY7zXhrBKHH4Mer7qZfrJ01LpSkO7VJfq3Ts4raq_8nwa_UMm4VlRgLOQqc7QRSfOpdLmrts3Fdp4OLfVaYSVRLOZg2oPwVNSnmnFz7fgYjNUajRtvVaLsaolGYqjGaYe_rvz--b71lMQDfdoDORndtGtz2-YMTDMmaYfoC1WCXig</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490699209</pqid></control><display><type>article</type><title>Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>VILLASENOR, Adriana ; FLATT, Shirley W ; MARINAC, Catherine ; NATARAJAN, Loki ; PIERCE, John P ; PATTERSON, Ruth E</creator><creatorcontrib>VILLASENOR, Adriana ; FLATT, Shirley W ; MARINAC, Catherine ; NATARAJAN, Loki ; PIERCE, John P ; PATTERSON, Ruth E</creatorcontrib><description>Serum C-reactive protein (CRP) is a marker of acute inflammatory response and has been associated with health outcomes in some studies. Inflammation and immune response may have potential prognostic implications for breast cancer survivors.
The Women's Healthy Eating and Living Study includes 2,919 early-stage breast cancer survivors with serum collected 2 years postdiagnosis and follow-up for clinical outcomes over approximately 7 years. CRP concentrations were measured using high-sensitivity electrochemiluminescence assay. Outcomes, including all-cause mortality, breast cancer-specific mortality, and additional breast cancer events were oncologist verified from medical records and death certificates. Cox proportional hazards models were conducted with adjustment for potential confounding factors to generate HRs and 95% confidence intervals (CI).
CRP concentrations in women diagnosed with breast cancer were associated with death due to any cause, death due to breast cancer, and additional breast cancer events, after adjustment for sociodemographic and cancer characteristics (lnCRP: P < 0.05 for all three outcomes). The HR for women with (vs. without) acute inflammation suggests a threshold effect on overall survival, rather than a dose-response relationship (≥ 10.0 mg/L vs. <1 mg/L: HR, 1.96; 95% CI, 1.22-3.13). Associations were similar for breast cancer-specific mortality (HR, 1.91; 95% CI, 1.13-3.23) and any additional breast cancer-related event (HR, 1.69; 95% CI, 1.17-2.43).
Acute inflammation status (CRP ≥ 10 mg/L) may be an important independent biomarker for long-term survival in breast cancer survivors.
Interventions to decrease circulating CRP concentrations in breast cancer survivors with acute inflammation may improve prognosis.</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.EPI-13-0852</identifier><identifier>PMID: 24220913</identifier><identifier>CODEN: CEBPE4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Breast Neoplasms - blood ; Breast Neoplasms - mortality ; C-Reactive Protein - metabolism ; Cohort Studies ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Prognosis ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Tumors ; United States - epidemiology ; Young Adult</subject><ispartof>Cancer epidemiology, biomarkers & prevention, 2014-01, Vol.23 (1), p.189-199</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-9a0dfd5207272848360262feb3b6180337a86008dd84c1ddd822f875ea45fc823</citedby><cites>FETCH-LOGICAL-c441t-9a0dfd5207272848360262feb3b6180337a86008dd84c1ddd822f875ea45fc823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3356,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28409641$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24220913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VILLASENOR, Adriana</creatorcontrib><creatorcontrib>FLATT, Shirley W</creatorcontrib><creatorcontrib>MARINAC, Catherine</creatorcontrib><creatorcontrib>NATARAJAN, Loki</creatorcontrib><creatorcontrib>PIERCE, John P</creatorcontrib><creatorcontrib>PATTERSON, Ruth E</creatorcontrib><title>Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study</title><title>Cancer epidemiology, biomarkers & prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>Serum C-reactive protein (CRP) is a marker of acute inflammatory response and has been associated with health outcomes in some studies. Inflammation and immune response may have potential prognostic implications for breast cancer survivors.
The Women's Healthy Eating and Living Study includes 2,919 early-stage breast cancer survivors with serum collected 2 years postdiagnosis and follow-up for clinical outcomes over approximately 7 years. CRP concentrations were measured using high-sensitivity electrochemiluminescence assay. Outcomes, including all-cause mortality, breast cancer-specific mortality, and additional breast cancer events were oncologist verified from medical records and death certificates. Cox proportional hazards models were conducted with adjustment for potential confounding factors to generate HRs and 95% confidence intervals (CI).
CRP concentrations in women diagnosed with breast cancer were associated with death due to any cause, death due to breast cancer, and additional breast cancer events, after adjustment for sociodemographic and cancer characteristics (lnCRP: P < 0.05 for all three outcomes). The HR for women with (vs. without) acute inflammation suggests a threshold effect on overall survival, rather than a dose-response relationship (≥ 10.0 mg/L vs. <1 mg/L: HR, 1.96; 95% CI, 1.22-3.13). Associations were similar for breast cancer-specific mortality (HR, 1.91; 95% CI, 1.13-3.23) and any additional breast cancer-related event (HR, 1.69; 95% CI, 1.17-2.43).
Acute inflammation status (CRP ≥ 10 mg/L) may be an important independent biomarker for long-term survival in breast cancer survivors.
Interventions to decrease circulating CRP concentrations in breast cancer survivors with acute inflammation may improve prognosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - mortality</subject><subject>C-Reactive Protein - metabolism</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Prognosis</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>United States - epidemiology</subject><subject>Young Adult</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkVtrGzEQhUVoyf0ntOilkJdNdN2V-lBojXMBQ02TkKcgZElrq6wlR9Ia8u-zS5ykfZqB-ebMcA4AXzA6x5iLC4w4r6Ss-fl0flNhWiHByR44xJyKqmk4_zT0b8wBOMr5L0KokZzvgwPCCEES00PwOI-5WK-XIWaf4aT647QpfuvgPMXifIA6WPgrOZ0LnOhgXIK3fdr6bUx55Tff4aUP1odlhm2Ka1hWDj5cT2fwtvT2-QR8bnWX3emuHoP7y-nd5Lqa_b66mfycVYYxXCqpkW0tJ6ghDRFM0BqRmrRuQRc1FojSRosaIWGtYAbboRDSioY7zXhrBKHH4Mer7qZfrJ01LpSkO7VJfq3Ts4raq_8nwa_UMm4VlRgLOQqc7QRSfOpdLmrts3Fdp4OLfVaYSVRLOZg2oPwVNSnmnFz7fgYjNUajRtvVaLsaolGYqjGaYe_rvz--b71lMQDfdoDORndtGtz2-YMTDMmaYfoC1WCXig</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>VILLASENOR, Adriana</creator><creator>FLATT, Shirley W</creator><creator>MARINAC, Catherine</creator><creator>NATARAJAN, Loki</creator><creator>PIERCE, John P</creator><creator>PATTERSON, Ruth E</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study</title><author>VILLASENOR, Adriana ; FLATT, Shirley W ; MARINAC, Catherine ; NATARAJAN, Loki ; PIERCE, John P ; PATTERSON, Ruth E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-9a0dfd5207272848360262feb3b6180337a86008dd84c1ddd822f875ea45fc823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - mortality</topic><topic>C-Reactive Protein - metabolism</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Prognosis</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>United States - epidemiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VILLASENOR, Adriana</creatorcontrib><creatorcontrib>FLATT, Shirley W</creatorcontrib><creatorcontrib>MARINAC, Catherine</creatorcontrib><creatorcontrib>NATARAJAN, Loki</creatorcontrib><creatorcontrib>PIERCE, John P</creatorcontrib><creatorcontrib>PATTERSON, Ruth E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VILLASENOR, Adriana</au><au>FLATT, Shirley W</au><au>MARINAC, Catherine</au><au>NATARAJAN, Loki</au><au>PIERCE, John P</au><au>PATTERSON, Ruth E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study</atitle><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>23</volume><issue>1</issue><spage>189</spage><epage>199</epage><pages>189-199</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><coden>CEBPE4</coden><abstract>Serum C-reactive protein (CRP) is a marker of acute inflammatory response and has been associated with health outcomes in some studies. Inflammation and immune response may have potential prognostic implications for breast cancer survivors.
The Women's Healthy Eating and Living Study includes 2,919 early-stage breast cancer survivors with serum collected 2 years postdiagnosis and follow-up for clinical outcomes over approximately 7 years. CRP concentrations were measured using high-sensitivity electrochemiluminescence assay. Outcomes, including all-cause mortality, breast cancer-specific mortality, and additional breast cancer events were oncologist verified from medical records and death certificates. Cox proportional hazards models were conducted with adjustment for potential confounding factors to generate HRs and 95% confidence intervals (CI).
CRP concentrations in women diagnosed with breast cancer were associated with death due to any cause, death due to breast cancer, and additional breast cancer events, after adjustment for sociodemographic and cancer characteristics (lnCRP: P < 0.05 for all three outcomes). The HR for women with (vs. without) acute inflammation suggests a threshold effect on overall survival, rather than a dose-response relationship (≥ 10.0 mg/L vs. <1 mg/L: HR, 1.96; 95% CI, 1.22-3.13). Associations were similar for breast cancer-specific mortality (HR, 1.91; 95% CI, 1.13-3.23) and any additional breast cancer-related event (HR, 1.69; 95% CI, 1.17-2.43).
Acute inflammation status (CRP ≥ 10 mg/L) may be an important independent biomarker for long-term survival in breast cancer survivors.
Interventions to decrease circulating CRP concentrations in breast cancer survivors with acute inflammation may improve prognosis.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>24220913</pmid><doi>10.1158/1055-9965.EPI-13-0852</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1055-9965 |
| ispartof | Cancer epidemiology, biomarkers & prevention, 2014-01, Vol.23 (1), p.189-199 |
| issn | 1055-9965 1538-7755 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3911892 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research |
| subjects | Adult Aged Biological and medical sciences Breast Neoplasms - blood Breast Neoplasms - mortality C-Reactive Protein - metabolism Cohort Studies Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Prognosis Randomized Controlled Trials as Topic Treatment Outcome Tumors United States - epidemiology Young Adult |
| title | Postdiagnosis C-Reactive Protein and Breast Cancer Survivorship: Findings from the WHEL Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T11%3A39%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postdiagnosis%20C-Reactive%20Protein%20and%20Breast%20Cancer%20Survivorship:%20Findings%20from%20the%20WHEL%20Study&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=VILLASENOR,%20Adriana&rft.date=2014-01-01&rft.volume=23&rft.issue=1&rft.spage=189&rft.epage=199&rft.pages=189-199&rft.issn=1055-9965&rft.eissn=1538-7755&rft.coden=CEBPE4&rft_id=info:doi/10.1158/1055-9965.EPI-13-0852&rft_dat=%3Cproquest_pubme%3E1490699209%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490699209&rft_id=info:pmid/24220913&rfr_iscdi=true |